Results 131 to 140 of about 80,955 (206)

Characterization of exceptional responders with long-term PARP inhibitor therapy in recurrent ovarian cancer: an analysis of 23 patients from Charité. [PDF]

Arch Gynecol Obstet
Glajzer J, Sehouli J, Woopen H, Braicu EI, Baum J, Grabowski JP.   +5 more
europepmc   +1 more source

Surgical Timing and Survival in Advanced High-Grade Serous Ovarian Cancer in the PARP Inhibitor Era. [PDF]

Cancers (Basel)
Kanno M, Fusegi A, Miyazaki N, Ozawa R, Netsu S, Aoki Y, Omi M, Nomura H, Yunokawa M, Kanao H.   +9 more
europepmc   +1 more source

Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know? [PDF]

Cancer Control
Kumari S, Umadevi K, Sundeep D.
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. [PDF]

Mol Oncol
Schmitz J, Bartkowiak AL, Rose M, Kolks N, Petzsch P, Solanki V, Stoffel A, Faßbender B, Lepping L, Volkamer J, Köhrer K, Seifert M, Mahmoudi T, Zuiverloon TCM, Niegisch G, Hoffmann MJ.   +15 more
europepmc   +1 more source

Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations. [PDF]

Oncologist
Castro E, Wang D, Paganelli S, Haltner A, Su N, Kirker M, Chang J, Samjoo IA.   +7 more
europepmc   +1 more source

Intersecting Anemias: PARP Inhibitor-Induced Toxicity and Autoimmune Hemolysis-A Case Report. [PDF]

EJHaem
Dereme J, Asonitis K, Grandoni F, Liapi A, Sarivalasis A, Tsilimidos G.   +5 more
europepmc   +1 more source

Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications. [PDF]

Cancer Med
Lin DI, Lawrence E, Danziger N, Ye H, Decker B, Gjoerup O, Graf RP, Ross JS, Huang RSP, Elvin JA, Mata DA, McKay RR.   +11 more
europepmc   +1 more source

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer. [PDF]

Nat Commun
Nan Y, Wang K, Hu M, Luo Q, Wu X, Yu X, Zhou X, Chen L, Li B, Cui Z, Liu Z.   +10 more
europepmc   +1 more source

Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance. [PDF]

Pharmaceutics
Xu L, Kong X, Zhang B, Ma H, Li X, Deng Y, Liu W, Ren W, Tang X, Zhang D.   +9 more
europepmc   +1 more source